Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection. (Q37879701)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 May 2011

Language	Label	Description	Also known as
English	Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.	scientific article published on 25 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

Elisabetta Cariani

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Cristina Rota

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Rosina Critelli

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Tommaso Trenti

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

25 May 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Clinical Chemistry and Laboratory Medicine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

49

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1247-1256

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Global burden of disease (GBD) for hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Chronic hepatitis C virus infection: genotyping and its clinical role

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-based therapy for chronic hepatitis C: current and future perspectives

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Impact of obesity on treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Immunological determinants of the outcomes from primary hepatitis C infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B and the control of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A whole-genome association study of major determinants for host control of HIV-1

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A haplotype map of the human genome

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon signaling and treatment outcome in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The recent breakthroughs in the understanding of host genomics in hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

What have we learned from the IL28 receptor knockout mouse?

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatitis C pharmacogenetics: state of the art in 2010.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Factors contributing to ribavirin-induced anemia

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Factors influencing ribavirin-induced hemolysis

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Functional study of the P32T ITPA variant associated with drug sensitivity in humans.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Pharmacogenetic significance of inosine triphosphatase

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Individual variation in inosine triphosphate accumulation in human erythrocytes

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37879701&oldid=1605217066"